Business Wire

Exclusive Group Transitions Leadership Team for Next Stage of Growth

Share

Exclusive Group, the global value-added services and technologies (VAST) group, today announced Andy Travers as its new SVP Worldwide Sales and Marketing. The ex-Fortinet and RSA executive will be responsible for leading the next phase of Exclusive’s growth strategy to build the world’s biggest specialist VAD in cybersecurity and cloud transformation with targeted revenues of $10bn over the next 5 years.

The appointment coincides with the news that Exclusive Group’s current COO, Barrie Desmond, has decided to step down at the end of 2018 to pursue other interests. Affectionately dubbed ‘Disruptive Desmond’, he has played a key role in developing Exclusive’s go-to-market proposition, market positioning and sales growth over the last 7 years.

Andy Travers is a 25-year veteran of IT channel sales excellence, achieving success at reseller, VAD and global vendor organisations. As SVP of Worldwide Sales and Marketing, Travers will be responsible for steering Exclusive to unprecedented revenues, heading up strategic alliances with major vendors, developing key relationships with GSIs and taking executive control of global services. His previous roles include SVP and VP Sales positions on both sides of the Atlantic for Fortinet, as well as VP EMEA stints at F5 Networks and, most recently, RSA Security.

Commenting on the changes Olivier Breittmayer, Exclusive Group’s CEO said, “Following our recent investment from Permira funds we set ourselves high expectations for executing against our new growth strategy. Andy has the skills and experience necessary to contribute to us achieving our goals and understands our unique culture and values having been in the orbit of Exclusive working with our vendors and channel partners for many years. We are delighted to have him onboard.

“Barrie’s decision to stand down at the end of the year is totally respected by myself and the board. We’ve worked well together these past 7 years, architecting and driving the growth of this business and telling the story only we can tell. It’s been a great journey together and we wish him all the best for the future.”

Commenting on his appointment Andy Travers said, “Exclusive has earned a worldwide reputation for doing what no other VAD has been able to do – delivering genuine value-add at scale. I’m joining at a pivotal time for the business as we commit to exploiting the global opportunities around cybersecurity and cloud transformation to reach another step-change in growth. The investors and management team have developed a winning strategy and now it’s all about the execution. I’m delighted to be joining and really looking forward to helping achieve the next phase of growth.”

Desmond and Travers will work closely together over the next few months to ensure a smooth transition.

Commenting on his decision to leave Exclusive at the end of the year, COO Barrie Desmond said, “My work here is done. We’ve had an incredible journey and built a VAD that continues to disrupt, grow sales at an extraordinary rate and expand its footprint at an astonishing tempo. Along the way we’ve reinvented Distribution and redefined value. But now it’s time for the next generation of disruptors to take on the challenge of growing the world’s largest specialist VAD.”

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Cohesive
Jon Bawden
+44 (0) 1291 626200
exclusivegroup@wearecohesive.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 11:00:00 EET | Press release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in

Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 11:00:00 EET | Press release

Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration

Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 11:00:00 EET | Press release

Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo

Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release

Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of

Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye